Jade Biosciences Reports Q3 2025 Financial Results
I'm PortAI, I can summarize articles.
Jade Biosciences reported a Q3 2025 net loss of $25.2 million due to increased R&D and G&A expenses. The company completed a merger and reverse stock split, presented promising preclinical data, and initiated a Phase 1 study. They raised $135 million to extend their cash runway into 2028. Analysts rate JBIO stock as a Buy with a $28 target, but Spark's AI Analyst views it as Underperform due to financial challenges. Jade Biosciences focuses on therapies for autoimmune diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments